Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 7/20 | 0.85 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.60 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9827537 | 0.93 | CYSLTR1 (0.83) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL9130463 | 0.92 | CYSLTR1 (1.00) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL26771295 | 0.89 | CYSLTR1 (0.77) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL7010090 | 0.89 | CYSLTR1 (0.84) | CYSLTR1GPBAR1ALOX5MRGPRX4CYSLTR2 | |
| SCHEMBL26771312 | 0.88 | CYSLTR1 (0.82) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL9828760 | 0.87 | CYSLTR1 (0.74) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL7005360 | 0.87 | CYSLTR1 (0.71) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL6089805 | 0.87 | CYSLTR1 (0.74) | CYSLTR1GPBAR1ALOX5CYSLTR2 | |
| SCHEMBL7454982 | 0.85 | CYSLTR1 (0.69) | CYSLTR1GPBAR1ALOX5MRGPRX4CYSLTR2 | |
| SCHEMBL6088531 | 0.84 | CYSLTR1 (0.67) | CYSLTR1GPBAR1ALOX5CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | AVENTIS PHARMACEUTICALS PRODUCTS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1267874-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | Aventis Pharma Deutschland GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| EP-1030665-A4 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARM PROD INC (US) | 2002-11-27 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| WO-2001066098-A2 | THERAPEUTIC USES OF PPAR MEDIATORS | AVENTIS PHARMA DEUTSCHLAND GMBH | 2001-09-13 | — | — | WO | disclosed |
| EP-1030665-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | Aventis Pharmaceuticals Products Inc. (US) | 2000-08-30 | — | — | EP | disclosed |
| WO-1999020275-A1 | THERAPEUTIC USES OF QUINOLINE DERIVATIVES | AVENTIS PHARMACEUTICALS PRODUCTS INC. (US) | 1999-04-29 | — | — | WO | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0315399-A2 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-05-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220373-A1 | Therapeutic uses of PPAR mediators | PPARG, PPARA, PPARD | CYSLTR1 297/4885GPBAR1 15/4885ALOX5 668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.